Abstract
Recently, there has been much advancement in the treatment of hormone receptor positive HER2-negative metastatic breast cancer. Understanding of the role of phosphatidylinositol-3-kinase (PI3K) in the pathologically activated PI3K/AKT/mTOR pathway has led to the development of PI3K inhibitors.
PIK3CA mutations occur in approximately 40% of patients with hormone receptor positive HER2-negative breast cancer. The PI3K specific inhibitor alpelisib has shown antitumor activity in clinical trials and based on the results of the SOLAR-1 registration study, it was included in the treatment of hormone receptor positive HER2-negative metastatic breast cancer with PI3KCA mutation.